- Home
- IBTA vs AKBA Comparison
IBTA vs AKBA Comparison
Compare IBTA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- AKBA
- Stock Information
- Founded
- IBTA 2011
- AKBA 2007
- Country
- IBTA United States
- AKBA United States
- Employees
- IBTA N/A
- AKBA N/A
- Industry
- IBTA
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- AKBA Health Care
- Exchange
- IBTA Nasdaq
- AKBA Nasdaq
- Market Cap
- IBTA 892.4M
- AKBA 861.7M
- IPO Year
- IBTA 2024
- AKBA 2014
- Fundamental
- Price
- IBTA $27.21
- AKBA $3.04
- Analyst Decision
- IBTA Hold
- AKBA Strong Buy
- Analyst Count
- IBTA 10
- AKBA 5
- Target Price
- IBTA $44.33
- AKBA $6.90
- AVG Volume (30 Days)
- IBTA 773.2K
- AKBA 4.0M
- Earning Date
- IBTA 08-13-2025
- AKBA 08-07-2025
- Dividend Yield
- IBTA N/A
- AKBA N/A
- EPS Growth
- IBTA 2512.20
- AKBA N/A
- EPS
- IBTA 2.84
- AKBA N/A
- Revenue
- IBTA $367,604,000.00
- AKBA $203,733,000.00
- Revenue This Year
- IBTA $6.62
- AKBA $27.95
- Revenue Next Year
- IBTA $15.30
- AKBA $43.88
- P/E Ratio
- IBTA $9.62
- AKBA N/A
- Revenue Growth
- IBTA 3.49
- AKBA 16.75
- 52 Week Low
- IBTA $22.50
- AKBA $1.24
- 52 Week High
- IBTA $79.80
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- AKBA 34.84
- Support Level
- IBTA N/A
- AKBA $2.92
- Resistance Level
- IBTA N/A
- AKBA $3.44
- Average True Range (ATR)
- IBTA 0.00
- AKBA 0.15
- MACD
- IBTA 0.00
- AKBA -0.06
- Stochastic Oscillator
- IBTA 0.00
- AKBA 13.79
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.